Results 151 to 160 of about 73,540 (330)

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

open access: yesBMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai   +14 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

open access: yesBMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu   +16 more
wiley   +1 more source

Prodrugs of acyclic nucleoside phosphonates

open access: yes
Numerous modified nucleosides and nucleotides exhibit potent antiviral properties. The goal of this thesis was to synthesize ten novel prodrugs of acyclic nucleoside phosphonates, which contain 2,6-diaminopurine as a nucleobase, namely (R)-PMPDAP and (R)-
Jaroš, Marek
core  

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

open access: yesBMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen   +9 more
wiley   +1 more source

Organelle‐Resolved Tetrazine‐trans‐Cyclooctene Click Chemistry for Cargo Delivery and Release

open access: yesChemistry – A European Journal, EarlyView.
Bioorthogonal click chemistry tools provide a means for specific intracellular conjugation of molecules. In this study, we used reactive tetrazine (Tz) and TCO moieties for labeling of organelles and organelle‐specific delivery and activation of doxorubicin prodrugs.
Oleh Durydivka   +6 more
wiley   +1 more source

A Stable Isopterin Mimic of a Potent Bacterial Stimulant of T Cells

open access: yesChemistry – A European Journal, EarlyView.
A microbial metabolite covalently binds immunological protein MR1 to potently activate specific lymphocytes called MAIT cells, but it is too unstable for biological applications. Here, using synthesis, assays, protein crystallography, and computer modelling, we report a water‐stable analogue that activates reporter cells expressing the MAIT T cell ...
Jeffrey Y. W. Mak   +9 more
wiley   +1 more source

Targeting Cancer Cells With Self‐Assembled Ru‐Polysaccharide Photocatalyst for Visible‐Light‐Induced Activation of Prodrugs

open access: yesChemistry – A European Journal, EarlyView.
Self‐assembled photocatalyst Ru(Ada‐bpy)(bpy)2⊂HACD targets cancer cells and catalyzes the prodrug to drug upon exposure to visible light, providing spatially and temporally control in cancer cells. This strategy achieves efficient, controllable, and targeted activation of prodrugs within cancer cells, laying the foundation of effectively reducing the ...
Jianghua Liu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy